Titre : Endotoxines

Endotoxines : Questions médicales fréquentes

Termes MeSH sélectionnés :

Platelet Transfusion
{ "@context": "https://schema.org", "@graph": [ { "@type": "MedicalWebPage", "name": "Endotoxines : Questions médicales les plus fréquentes", "headline": "Endotoxines : Comprendre les symptômes, diagnostics et traitements", "description": "Guide complet et accessible sur les Endotoxines : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.", "datePublished": "2024-02-12", "dateModified": "2025-05-07", "inLanguage": "fr", "medicalAudience": [ { "@type": "MedicalAudience", "name": "Grand public", "audienceType": "Patient", "healthCondition": { "@type": "MedicalCondition", "name": "Endotoxines" }, "suggestedMinAge": 18, "suggestedGender": "unisex" }, { "@type": "MedicalAudience", "name": "Médecins", "audienceType": "Physician", "geographicArea": { "@type": "AdministrativeArea", "name": "France" } }, { "@type": "MedicalAudience", "name": "Chercheurs", "audienceType": "Researcher", "geographicArea": { "@type": "AdministrativeArea", "name": "International" } } ], "reviewedBy": { "@type": "Person", "name": "Dr Olivier Menir", "jobTitle": "Expert en Médecine", "description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale", "url": "/static/pages/docteur-olivier-menir.html", "alumniOf": { "@type": "EducationalOrganization", "name": "Université Paris Descartes" } }, "isPartOf": { "@type": "MedicalWebPage", "name": "Toxines bactériennes", "url": "https://questionsmedicales.fr/mesh/D001427", "about": { "@type": "MedicalCondition", "name": "Toxines bactériennes", "code": { "@type": "MedicalCode", "code": "D001427", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D23.946.123" } } }, "hasPart": [ { "@type": "MedicalWebPage", "name": "Lipopolysaccharides", "alternateName": "Lipopolysaccharides", "url": "https://questionsmedicales.fr/mesh/D008070", "about": { "@type": "MedicalCondition", "name": "Lipopolysaccharides", "code": { "@type": "MedicalCode", "code": "D008070", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D23.946.123.329.500" } }, "hasPart": [ { "@type": "MedicalWebPage", "name": "Lipide A", "alternateName": "Lipid A", "url": "https://questionsmedicales.fr/mesh/D008050", "about": { "@type": "MedicalCondition", "name": "Lipide A", "code": { "@type": "MedicalCode", "code": "D008050", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D23.946.123.329.500.500" } } }, { "@type": "MedicalWebPage", "name": "Antigènes O", "alternateName": "O Antigens", "url": "https://questionsmedicales.fr/mesh/D019081", "about": { "@type": "MedicalCondition", "name": "Antigènes O", "code": { "@type": "MedicalCode", "code": "D019081", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D23.946.123.329.500.600" } } } ] } ], "about": { "@type": "MedicalCondition", "name": "Endotoxines", "alternateName": "Endotoxins", "code": { "@type": "MedicalCode", "code": "D004731", "codingSystem": "MeSH" } }, "author": [ { "@type": "Person", "name": "Johannes Reich", "url": "https://questionsmedicales.fr/author/Johannes%20Reich", "affiliation": { "@type": "Organization", "name": "Microcoat Biotechnologie GmbH, Am Neuland 3, 82347 Bernried am Stanberger See, Germany. j.reich@microcoat.de." } }, { "@type": "Person", "name": "Guy C Brown", "url": "https://questionsmedicales.fr/author/Guy%20C%20Brown", "affiliation": { "@type": "Organization", "name": "Department of Biochemistry, University of Cambridge, Cambridge, CB2 1QW, UK. gcb3@cam.ac.uk." } }, { "@type": "Person", "name": "John A Kellum", "url": "https://questionsmedicales.fr/author/John%20A%20Kellum", "affiliation": { "@type": "Organization", "name": "Department of Critical Care Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania, USA." } }, { "@type": "Person", "name": "Gary Hannon", "url": "https://questionsmedicales.fr/author/Gary%20Hannon", "affiliation": { "@type": "Organization", "name": "Nanomedicine and Molecular Imaging Group, Department of Clinical Medicine, Trinity Translational Medicine Institute, Dublin, Ireland." } }, { "@type": "Person", "name": "Adriele Prina-Mello", "url": "https://questionsmedicales.fr/author/Adriele%20Prina-Mello", "affiliation": { "@type": "Organization", "name": "Nanomedicine and Molecular Imaging Group, Department of Clinical Medicine, Trinity Translational Medicine Institute, Dublin, Ireland." } } ], "citation": [ { "@type": "ScholarlyArticle", "name": "Herombopag promotes platelet engraftment and decreases platelet transfusion after allogeneic hematopoietic stem cell transplantation.", "datePublished": "2023-01-20", "url": "https://questionsmedicales.fr/article/36599813", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1111/ejh.13925" } }, { "@type": "ScholarlyArticle", "name": "Systematic reviews on platelet transfusions: Is there unnecessary duplication of effort? A scoping review.", "datePublished": "2022-12-01", "url": "https://questionsmedicales.fr/article/36454598", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1111/vox.13387" } }, { "@type": "ScholarlyArticle", "name": "The safety of ABO minor incompatible platelets transfusions using a rapid infuser.", "datePublished": "2024-02-01", "url": "https://questionsmedicales.fr/article/38299721", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1111/trf.17739" } }, { "@type": "ScholarlyArticle", "name": "Therapeutic Efficacy of Platelet Transfusion and Analysis of Influencing Factors in 364 patients.", "datePublished": "2023-02-09", "url": "https://questionsmedicales.fr/article/36758527", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1159/000529542" } }, { "@type": "ScholarlyArticle", "name": "Platelet transfusion practice pattern before and after implementation of a local restrictive transfusion protocol in a neonatal intensive care unit.", "datePublished": "2022-11-12", "url": "https://questionsmedicales.fr/article/36369934", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1111/trf.17184" } } ], "breadcrumb": { "@type": "BreadcrumbList", "itemListElement": [ { "@type": "ListItem", "position": 1, "name": "questionsmedicales.fr", "item": "https://questionsmedicales.fr" }, { "@type": "ListItem", "position": 2, "name": "Facteurs biologiques", "item": "https://questionsmedicales.fr/mesh/D001685" }, { "@type": "ListItem", "position": 3, "name": "Toxines biologiques", "item": "https://questionsmedicales.fr/mesh/D014118" }, { "@type": "ListItem", "position": 4, "name": "Toxines bactériennes", "item": "https://questionsmedicales.fr/mesh/D001427" }, { "@type": "ListItem", "position": 5, "name": "Endotoxines", "item": "https://questionsmedicales.fr/mesh/D004731" } ] } }, { "@type": "MedicalWebPage", "name": "Article complet : Endotoxines - Questions et réponses", "headline": "Questions et réponses médicales fréquentes sur Endotoxines", "description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.", "datePublished": "2025-05-13", "inLanguage": "fr", "hasPart": [ { "@type": "MedicalWebPage", "name": "Diagnostic", "headline": "Diagnostic sur Endotoxines", "description": "Comment diagnostiquer une intoxication par endotoxines ?\nQuels tests sont utilisés pour détecter les endotoxines ?\nQuels signes cliniques indiquent une exposition aux endotoxines ?\nLes endotoxines peuvent-elles être détectées dans le sang ?\nQuel rôle joue la culture bactérienne dans le diagnostic ?", "url": "https://questionsmedicales.fr/mesh/D004731?mesh_terms=Platelet+Transfusion&page=3#section-diagnostic" }, { "@type": "MedicalWebPage", "name": "Symptômes", "headline": "Symptômes sur Endotoxines", "description": "Quels sont les symptômes d'une intoxication par endotoxines ?\nComment les endotoxines affectent-elles le système immunitaire ?\nLes endotoxines causent-elles des douleurs ?\nQuels signes indiquent un choc septique dû aux endotoxines ?\nLes symptômes varient-ils selon l'exposition ?", "url": "https://questionsmedicales.fr/mesh/D004731?mesh_terms=Platelet+Transfusion&page=3#section-symptômes" }, { "@type": "MedicalWebPage", "name": "Prévention", "headline": "Prévention sur Endotoxines", "description": "Comment prévenir l'exposition aux endotoxines ?\nLes vaccins peuvent-ils prévenir les infections à endotoxines ?\nQuelles mesures de sécurité en laboratoire sont nécessaires ?\nLes antibiotiques préventifs sont-ils efficaces ?\nComment réduire le risque d'infections nosocomiales ?", "url": "https://questionsmedicales.fr/mesh/D004731?mesh_terms=Platelet+Transfusion&page=3#section-prévention" }, { "@type": "MedicalWebPage", "name": "Traitements", "headline": "Traitements sur Endotoxines", "description": "Quel est le traitement principal pour une intoxication par endotoxines ?\nLes corticostéroïdes sont-ils efficaces contre les endotoxines ?\nComment traiter le choc septique causé par des endotoxines ?\nLes antidotes existent-ils pour les endotoxines ?\nQuelle est l'importance de la prise en charge précoce ?", "url": "https://questionsmedicales.fr/mesh/D004731?mesh_terms=Platelet+Transfusion&page=3#section-traitements" }, { "@type": "MedicalWebPage", "name": "Complications", "headline": "Complications sur Endotoxines", "description": "Quelles sont les complications possibles d'une intoxication par endotoxines ?\nComment les endotoxines affectent-elles les organes ?\nLe syndrome de détresse respiratoire est-il lié aux endotoxines ?\nLes endotoxines peuvent-elles causer des dommages neurologiques ?\nQuel est le pronostic après une exposition aux endotoxines ?", "url": "https://questionsmedicales.fr/mesh/D004731?mesh_terms=Platelet+Transfusion&page=3#section-complications" }, { "@type": "MedicalWebPage", "name": "Facteurs de risque", "headline": "Facteurs de risque sur Endotoxines", "description": "Quels sont les principaux facteurs de risque d'intoxication par endotoxines ?\nLes infections bactériennes augmentent-elles le risque d'endotoxines ?\nLes interventions chirurgicales augmentent-elles le risque ?\nLe diabète est-il un facteur de risque pour les endotoxines ?\nLes conditions de vie insalubres augmentent-elles le risque ?", "url": "https://questionsmedicales.fr/mesh/D004731?mesh_terms=Platelet+Transfusion&page=3#section-facteurs de risque" } ] }, { "@type": "FAQPage", "mainEntity": [ { "@type": "Question", "name": "Comment diagnostiquer une intoxication par endotoxines ?", "position": 1, "acceptedAnswer": { "@type": "Answer", "text": "Le diagnostic repose sur des tests sanguins, cultures et évaluation clinique." } }, { "@type": "Question", "name": "Quels tests sont utilisés pour détecter les endotoxines ?", "position": 2, "acceptedAnswer": { "@type": "Answer", "text": "Le test de limule et les tests ELISA sont couramment utilisés." } }, { "@type": "Question", "name": "Quels signes cliniques indiquent une exposition aux endotoxines ?", "position": 3, "acceptedAnswer": { "@type": "Answer", "text": "Fièvre, frissons, hypotension et tachycardie sont des signes fréquents." } }, { "@type": "Question", "name": "Les endotoxines peuvent-elles être détectées dans le sang ?", "position": 4, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des tests spécifiques peuvent détecter les endotoxines dans le sang." } }, { "@type": "Question", "name": "Quel rôle joue la culture bactérienne dans le diagnostic ?", "position": 5, "acceptedAnswer": { "@type": "Answer", "text": "Elle permet d'identifier la source bactérienne des endotoxines." } }, { "@type": "Question", "name": "Quels sont les symptômes d'une intoxication par endotoxines ?", "position": 6, "acceptedAnswer": { "@type": "Answer", "text": "Les symptômes incluent fièvre, frissons, douleurs abdominales et confusion." } }, { "@type": "Question", "name": "Comment les endotoxines affectent-elles le système immunitaire ?", "position": 7, "acceptedAnswer": { "@type": "Answer", "text": "Elles provoquent une réponse inflammatoire excessive, pouvant mener à un choc." } }, { "@type": "Question", "name": "Les endotoxines causent-elles des douleurs ?", "position": 8, "acceptedAnswer": { "@type": "Answer", "text": "Oui, elles peuvent provoquer des douleurs abdominales et musculaires." } }, { "@type": "Question", "name": "Quels signes indiquent un choc septique dû aux endotoxines ?", "position": 9, "acceptedAnswer": { "@type": "Answer", "text": "Hypotension, tachycardie, confusion et peau froide sont des signes clés." } }, { "@type": "Question", "name": "Les symptômes varient-ils selon l'exposition ?", "position": 10, "acceptedAnswer": { "@type": "Answer", "text": "Oui, l'intensité des symptômes dépend de la dose et de la durée d'exposition." } }, { "@type": "Question", "name": "Comment prévenir l'exposition aux endotoxines ?", "position": 11, "acceptedAnswer": { "@type": "Answer", "text": "Éviter les environnements contaminés et respecter les protocoles d'hygiène." } }, { "@type": "Question", "name": "Les vaccins peuvent-ils prévenir les infections à endotoxines ?", "position": 12, "acceptedAnswer": { "@type": "Answer", "text": "Il n'existe pas de vaccin spécifique contre les endotoxines, mais contre certaines bactéries." } }, { "@type": "Question", "name": "Quelles mesures de sécurité en laboratoire sont nécessaires ?", "position": 13, "acceptedAnswer": { "@type": "Answer", "text": "Utiliser des équipements de protection individuelle et des procédures de désinfection." } }, { "@type": "Question", "name": "Les antibiotiques préventifs sont-ils efficaces ?", "position": 14, "acceptedAnswer": { "@type": "Answer", "text": "Ils peuvent être utilisés dans certains cas à risque, mais pas systématiquement." } }, { "@type": "Question", "name": "Comment réduire le risque d'infections nosocomiales ?", "position": 15, "acceptedAnswer": { "@type": "Answer", "text": "Améliorer l'hygiène hospitalière et le contrôle des infections est essentiel." } }, { "@type": "Question", "name": "Quel est le traitement principal pour une intoxication par endotoxines ?", "position": 16, "acceptedAnswer": { "@type": "Answer", "text": "Le traitement inclut des antibiotiques et des soins de soutien pour stabiliser le patient." } }, { "@type": "Question", "name": "Les corticostéroïdes sont-ils efficaces contre les endotoxines ?", "position": 17, "acceptedAnswer": { "@type": "Answer", "text": "Ils peuvent réduire l'inflammation, mais leur utilisation est controversée." } }, { "@type": "Question", "name": "Comment traiter le choc septique causé par des endotoxines ?", "position": 18, "acceptedAnswer": { "@type": "Answer", "text": "Le traitement nécessite des fluides intraveineux et des vasopresseurs." } }, { "@type": "Question", "name": "Les antidotes existent-ils pour les endotoxines ?", "position": 19, "acceptedAnswer": { "@type": "Answer", "text": "Il n'existe pas d'antidote spécifique, le traitement est symptomatique." } }, { "@type": "Question", "name": "Quelle est l'importance de la prise en charge précoce ?", "position": 20, "acceptedAnswer": { "@type": "Answer", "text": "Une prise en charge rapide améliore les chances de survie et réduit les complications." } }, { "@type": "Question", "name": "Quelles sont les complications possibles d'une intoxication par endotoxines ?", "position": 21, "acceptedAnswer": { "@type": "Answer", "text": "Les complications incluent le choc septique, l'insuffisance organique et la mort." } }, { "@type": "Question", "name": "Comment les endotoxines affectent-elles les organes ?", "position": 22, "acceptedAnswer": { "@type": "Answer", "text": "Elles peuvent provoquer une défaillance multi-organique en raison de l'inflammation." } }, { "@type": "Question", "name": "Le syndrome de détresse respiratoire est-il lié aux endotoxines ?", "position": 23, "acceptedAnswer": { "@type": "Answer", "text": "Oui, l'inflammation pulmonaire peut entraîner un syndrome de détresse respiratoire." } }, { "@type": "Question", "name": "Les endotoxines peuvent-elles causer des dommages neurologiques ?", "position": 24, "acceptedAnswer": { "@type": "Answer", "text": "Elles peuvent provoquer des troubles neurologiques en raison de l'inflammation systémique." } }, { "@type": "Question", "name": "Quel est le pronostic après une exposition aux endotoxines ?", "position": 25, "acceptedAnswer": { "@type": "Answer", "text": "Le pronostic dépend de la rapidité du traitement et de la gravité de l'exposition." } }, { "@type": "Question", "name": "Quels sont les principaux facteurs de risque d'intoxication par endotoxines ?", "position": 26, "acceptedAnswer": { "@type": "Answer", "text": "Les patients immunodéprimés, les personnes âgées et les hospitalisés sont à risque." } }, { "@type": "Question", "name": "Les infections bactériennes augmentent-elles le risque d'endotoxines ?", "position": 27, "acceptedAnswer": { "@type": "Answer", "text": "Oui, les infections par des bactéries Gram-négatives sont un facteur de risque majeur." } }, { "@type": "Question", "name": "Les interventions chirurgicales augmentent-elles le risque ?", "position": 28, "acceptedAnswer": { "@type": "Answer", "text": "Oui, les interventions chirurgicales peuvent exposer à des endotoxines, surtout en cas d'infection." } }, { "@type": "Question", "name": "Le diabète est-il un facteur de risque pour les endotoxines ?", "position": 29, "acceptedAnswer": { "@type": "Answer", "text": "Oui, le diabète peut affaiblir le système immunitaire et augmenter le risque d'infections." } }, { "@type": "Question", "name": "Les conditions de vie insalubres augmentent-elles le risque ?", "position": 30, "acceptedAnswer": { "@type": "Answer", "text": "Oui, elles favorisent la prolifération bactérienne et l'exposition aux endotoxines." } } ] } ] }

Sources (7110 au total)

Systematic reviews on platelet transfusions: Is there unnecessary duplication of effort? A scoping review.

Platelet transfusions are used across multiple patient populations to prevent and correct bleeding. This scoping review aimed to map the currently available systematic reviews (SRs) and evidence-based... A systematic literature search was conducted in seven databases for SRs on effectiveness (including dose and timing, transfusion trigger and ratio to other blood products), production modalities and d... We identified 110 SRs. The majority focused on clinical effectiveness, including prophylactic or therapeutic transfusions compared to no platelet transfusion (34 SRs), prophylactic compared to therape... An interactive evidence map of SRs and evidence-based guidelines in the field of platelet transfusion has been developed and identified multiple reviews. This work serves as a tool for researchers loo...

The safety of ABO minor incompatible platelets transfusions using a rapid infuser.

Administering platelets through a rapid infuser is proven to be safe. However, the clinical significance of infusing ABO-incompatible platelets with red blood cells (RBCs) in a rapid infuser remains u... Seven in vitro studies were performed including five cases (type A RBCs and type O platelets) and two controls (type A RBCs and platelets). Anti-A titers were measured in platelet units. An RBC unit a... The post-mix DAT was positive for IgG in all test samples (5/5), and weakly positive for complement in 3/5. The changes in free Hb in test cases between measured and calculated post-mix spanned -2.2 t... Our study suggested that mixing ABO-incompatible platelets with RBCs in a rapid infuser does not induce in vitro hemolysis. These findings support the use of rapid infusers regardless of platelet comp...

Therapeutic Efficacy of Platelet Transfusion and Analysis of Influencing Factors in 364 patients.

The aims of this study were to observe the therapeutic effect of platelet (PLT) transfusion and to analyze influencing factors for the sake of providing useful clues for improving the efficacy of PLT ... Included in this study were patients who received PLT transfusion in the affiliated hospital of Nantong University. Patients' sex, age, height, weight, PLT transfusion status, and 20-24-h PLT count be... A total of 364 patients received 1,060 PLT transfusions, including 728 successful transfusions and 332 unsuccessful transfusions. When the patients were grouped according to different etiologies, sign... To reduce PTR, multiple factors should be considered comprehensively when PLT transfusion therapy is to be implemented in clinical practice. PLT antibody is the main immune factor causing PTR....

Platelet transfusion practice pattern before and after implementation of a local restrictive transfusion protocol in a neonatal intensive care unit.

Following the results of the PlaNeT-2 randomized controlled trial showing decreased morbidity and mortality in neonates transfused at a threshold of 25 versus 50 × 10... Prospective observational cohort chart-review study comparing all neonates consecutively admitted to the NICU during two 5-months periods: 2013 (before; N = 401) versus 2021 (after; N = 402). Possible... Mean (± standard deviation) gestational age and birth weight were 34.9 ± 4.2 weeks and 2.5 ± 1.0 kg, respectively. In 2021, 5.0% were platelet-transfused versus 9.2% in 2013 (p = .027). Platelet trans... Restrictive local transfusion thresholds in a NICU decreased the proportion of platelet-transfused neonates by 46% and reduced donor exposure in transfused patients....

Two-year outcomes following a randomised platelet transfusion trial in preterm infants.

Assess mortality and neurodevelopmental outcomes at 2 years of corrected age in children who participated in the PlaNeT-2/MATISSE (Platelets for Neonatal Transfusion - 2/Management of Thrombocytopenia... Randomised clinical trial, enrolling from June 2011 to August 2017. Follow-up was complete by January 2020. Caregivers were not blinded; however, outcome assessors were blinded to treatment group.... 43 level II/III/IV neonatal intensive care units (NICUs) across UK, Netherlands and Ireland.... 660 infants born at less than 34 weeks' gestation with platelet counts less than 50×10... Infants were randomised to undergo a platelet transfusion at platelet count thresholds of 50×10... Our prespecified long-term follow-up outcome was a composite of death or neurodevelopmental impairment (developmental delay, cerebral palsy, seizure disorder, profound hearing or vision loss) at 2 yea... Follow-up data were available for 601 of 653 (92%) eligible participants. Of the 296 infants assigned to the higher threshold group, 147 (50%) died or survived with neurodevelopmental impairment, as c... Infants randomised to a higher platelet transfusion threshold of 50×10... ISRCTN87736839....

Aged versus fresh autologous platelet transfusion in a two-hit healthy volunteer model of transfusion-related acute lung injury.

Transfusion-related acute lung injury (TRALI) is a severe complication of blood transfusion that is thought of as a two-hit event: first the underlying patient condition (e.g., sepsis), and then the t... In a randomized controlled trial, 18 healthy male volunteers received a first hit of experimental endotoxemia (2 ng/kg lipopolysaccharide), and a second hit of fresh (2-day old) or aged (7-day old) au... All subjects reacted adequately to lipopolysaccharide infusion and satisfied SIRS criteria (increased pulse [>90/min] and temperature [>38°C]). There were no differences between the saline, fresh, and... In a human endotoxemia model of autologous platelet transfusion, with an adequate first hit and platelet storage lesion, transfusion of 7-day-old PC does not increase pulmonary inflammation compared w...

A randomized cross-over study of cryopreserved platelets in prophylactic transfusions of thrombocytopenic patients.

The short shelf-life of liquid-stored platelets (LP) at 20-24°C poses shortage and wastage challenges. Cryopreserved platelets have significantly extended shelf-life, and were safe and efficacious for... We performed a phase 1b/2a randomized cross-over study comparing the safety and efficacy of cryopreserved buffy coat-derived pooled platelets (CP) to LP in the prophylactic transfusions of thrombocyto... A total of 18 adults were randomly assigned 1:1 to CP and LP for their first thrombocytopenic period (TP) of up to 28-days. A total of 14 crossed over to the other platelet-arm for the second TP. Over... During shortages, CP may supplement LP in prophylactic transfusions of thrombocytopenic patients....